Theratechnologies (OTCMKTS:THERF) and Adamis Pharmaceuticals (NASDAQ:ADMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Earnings & Valuation
This table compares Theratechnologies and Adamis Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Theratechnologies||$45.18 million||4.12||-$4.66 million||N/A||N/A|
|Adamis Pharmaceuticals||$22.11 million||3.95||-$29.31 million||($0.55)||-2.15|
This is a summary of current recommendations and price targets for Theratechnologies and Adamis Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Theratechnologies currently has a consensus price target of $6.00, indicating a potential upside of 147.93%. Adamis Pharmaceuticals has a consensus price target of $1.25, indicating a potential upside of 5.93%. Given Theratechnologies’ higher probable upside, analysts plainly believe Theratechnologies is more favorable than Adamis Pharmaceuticals.
Insider and Institutional Ownership
1.4% of Theratechnologies shares are owned by institutional investors. Comparatively, 15.7% of Adamis Pharmaceuticals shares are owned by institutional investors. 5.9% of Adamis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Theratechnologies and Adamis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Theratechnologies has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.
Theratechnologies beats Adamis Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.